<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04930549</url>
  </required_header>
  <id_info>
    <org_study_id>2021/0188/HP</org_study_id>
    <nct_id>NCT04930549</nct_id>
  </id_info>
  <brief_title>Vascular Impact of Dapagliflozin in CKD Patients (DAPAVASC)</brief_title>
  <acronym>DAPAVASC</acronym>
  <official_title>Impact of Dapagliflozin on Vascular Function in Chronic Kidney Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine whether dapaglfiflozin 12-week administration is associated with&#xD;
      a beneficial impact on the vasculature of patients with chronic kidney disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, randomized, double-blind studies evaluating the impact of once-daily&#xD;
      dapagliflozin 10 mg versus placebo for 12 weeks on endothelial function, as primary endpoint,&#xD;
      will be conducted in 56 patients with chronic kidney disease (eGFR ≥25 and ≤60 mL/min/1.73m2&#xD;
      by CKD-EPI) and without diabetes (fasting glycemia≥1.26 mg/dL, oral hypoglycemic agents or&#xD;
      insulin) on top of standard treatment (n=27 per group). Indexes of arterial stiffness,&#xD;
      cardiovascular coupling, cardiac function and plasma concentrations of endothelial,&#xD;
      inflammatory and oxidative stress biomarkers will be assessed as secondary endpoints.&#xD;
      Patients will be recruited in the Departments of Cardiology and Nephrology of Rouen&#xD;
      University Hospital. The study will include an inclusion visit (V1), 2 exploration visits&#xD;
      performed before (V2) and 12 weeks (V3) after treatment initiation, and 1 output study (V4).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline of brachial artery endothelial function using echography</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in brachial artery flow-mediated dilatation in response to post-ischemia hyperemia using difference of brachial artery diameter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of arterial stiffness using applanation tonometry</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in carotid-to-femoral pulse wave velocity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of carotid artery geometry using echography (1)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in carotid diastolic diameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of carotid artery geometry using echography (2)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in carotid intima-media thickness using echography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of cardiac function by impedance cardiography (1)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in cardiac output</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of cardiac function by impedance cardiography (2)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in stroke volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of cardiac function by impedance cardiography (3)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in ejection fraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of cardiac function by impedance cardiography (4)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in end-diastolic volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of cardiac function by impedance cardiography (5)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in total peripheral resistance,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of cardiac function by impedance cardiography (6)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in left ventricular end-systolic elastance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of epoxyeicosatrienoic acid bioavailability</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in epoxyeicosatroenoic acid bioavailibility during heating</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of plasma NO bioavailability</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in plasma nitrite bioavailibility during heating</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Renal Insufficiency, Chronic</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin 10Mg Tab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapagliflozin 10 mg film-coated tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identical film-coated tablets without dapagliflozin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 10Mg Tab</intervention_name>
    <description>Patients receive dapagliflozin 10mg tablets once a day during 12 weeks</description>
    <arm_group_label>Dapagliflozin 10Mg Tab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients receive placebo tablets once a day during 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>impedance cardiography</intervention_name>
    <description>impedance cardiography (PhysioFlow® PF-05 Lab1TM, Manatec Biomedical) is done for evaluation of cardiac function</description>
    <arm_group_label>Dapagliflozin 10Mg Tab</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Applanation tonometry</intervention_name>
    <description>Applanation tonometry will be done using SphygmoCor®, Hogimed) is done for evaluation of arterial stiffness</description>
    <arm_group_label>Dapagliflozin 10Mg Tab</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>post-ischemic hyperemia of forearm</intervention_name>
    <description>An arterial occlusion cuff will be placed on the forearm, and will be deflated to allow post-ischemic hyperemia with the continuous measurements of brachial artery diameter and blood flow velocity by high-resolution echotracking coupled to a Doppler system (ArtLab system®)</description>
    <arm_group_label>Dapagliflozin 10Mg Tab</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>haemodynamics parameters</intervention_name>
    <description>haemodynamics parameters will be evaluated using automatic oscillometric recorder</description>
    <arm_group_label>Dapagliflozin 10Mg Tab</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic kidney disease (eGFR ≥25 and ≤60 mL/min/1.73m² by CKD-EPI)&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Receiving a stable dose of an ACE inhibitor or ARB for at least 12 weeks before&#xD;
             screening or patients who were documented to be intolerant to ACE inhibitors or ARBs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 and type 2 diabetes (fasting glycemia≥126 mg/dL or use of oral hypoglycemic&#xD;
             agents or insulin)&#xD;
&#xD;
          -  Recessive or autosomal dominant polycystic kidney disease&#xD;
&#xD;
          -  Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis&#xD;
&#xD;
          -  Lupus nephritis&#xD;
&#xD;
          -  Receiving cytotoxic therapy, immunosuppressive therapy or other immunotherapy for&#xD;
             primary or secondary renal disease within 6 months prior to enrolment&#xD;
&#xD;
          -  History of organ transplantation&#xD;
&#xD;
          -  Body weight &gt; 35 kg/m²&#xD;
&#xD;
          -  Receiving therapy with a sodium glucose co-transporter 2 (SGLT2) inhibitor within 8&#xD;
             weeks prior to enrolment or previous intolerance of an SGLT2 inhibitor&#xD;
&#xD;
          -  Patients with NYHA class IV congestive heart failure at the time of enrolment&#xD;
&#xD;
          -  Myocardial infarction, unstable angina, stroke or transient ischemic attack (TIA)&#xD;
             within 12 weeks prior to enrolment&#xD;
&#xD;
          -  Coronary revascularization (percutaneous coronary intervention or coronary artery&#xD;
             bypass grafting) or valvular repair/replacement within 12 weeks prior to enrolment or&#xD;
             is planned to undergo any of these procedures after randomization&#xD;
&#xD;
          -  Active malignancy requiring treatment at the time of enrolment or is planned to&#xD;
             undergo any treatment after randomization&#xD;
&#xD;
          -  Severe hepatic impairment (Child-Pugh class C)&#xD;
&#xD;
          -  History of frequent genital mycotic infections (&gt;2)&#xD;
&#xD;
          -  Current pregnancy OR women of child-bearing potential (ie, those who are not&#xD;
             chemically or surgically sterilized or who are not post-menopausal) who are not&#xD;
             willing to use a medically accepted method of contraception that is considered&#xD;
             reliable in the judgment of the investigator OR women who have a positive pregnancy&#xD;
             test at enrolment or exploration visits OR women who are breast-feeding&#xD;
&#xD;
          -  Contraindications to use glyceryl trinitrate (in particular allergy to nitrates or&#xD;
             concomitant use of vasodilators)&#xD;
&#xD;
          -  Participation in another clinical study with an investigational product during the&#xD;
             last month prior to enrolment&#xD;
&#xD;
          -  Inability of the patient, in the opinion of the investigator, to understand and/or&#xD;
             comply with procedures and/or follow-up OR any conditions that, in the opinion of the&#xD;
             investigator, may render the patient unable to complete the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominique Guerrot, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Rouen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeremy Bellien, PharmD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Rouen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julien Blot</last_name>
    <phone>+33232884035</phone>
    <email>julien.blot@chu-rouen.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeremy Bellien, MD, PhD</last_name>
    <phone>+33232881428</phone>
    <email>jeremy.bellien@chu-rouen.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Nephrology</name>
      <address>
        <city>Bois-Guillaume</city>
        <zip>76230</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Dominique Guerrot, MD,PhD</last_name>
      <phone>+33232885446</phone>
      <email>dominique.guerrot@chu-rouen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Pharmacology</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jeremy Bellien, PHarmD, PhD</last_name>
      <phone>+33232881428</phone>
      <email>jeremy.bellien@chu-rouen.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 3, 2021</study_first_submitted>
  <study_first_submitted_qc>June 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

